newsfilter
← Latest News
Business Wire·

Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting

  • Obsidian Therapeutics presented updated pooled safety data and efficacy updates for amsokigene autoleucel (amsoki-cel) at the SITC 2026 Annual Meeting in Phoenix, AZ.
  • The presentation covered data from the Phase 1 first-in-human study & the Phase 1/2 Agni-01 multicenter study involving patients with immune-checkpoint inhibitor-resistant advanced melanoma.
  • Efficacy updates focused on the 15 patients in the Agni-01 study treated at the recommended Phase 2 dose.
  • Two posters were presented on November 7, 2026: one detailing pooled safety & updated efficacy with a minimally invasive, low-dose lymphodepletion, & IL2-free regimen (Abstract 566), & another describing the trial-in-progress Phase 2 registration-enabling cohort (Abstract 570).
  • Amsoki-cel is an engineered tumor-infiltrating lymphocyte therapy armored with pharmacologically regulatable membrane-bound IL15, developed using Obsidian's proprietary cytoDRiVE platform.
  • The Agni-01 trial (NCT06060613) is currently evaluating amsoki-cel in patients with advanced solid tumors.